Ardelyx-AstraZeneca Licensing Agreement Earns Outstanding Partnering Deal of the Year

BayBio

December 05, 2013

BayBio awarded the Ardelyx-AstraZeneca licensing agreement the “Pantheon DiNA Outstanding Partnering” award. 

Latham advised Ardelyx in its worldwide exclusive licensing agreement with AstraZeneca for a therapeutic NH3 inhibitor, a deal valued up to US$870 million.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.